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CONDENSATION OF THE RESEARCH 
To characterize the interLeukin converting enzyme (ICE) required for inter-
leukin-/(3 activation 
Human ICE was purified . A minimal substrate and inhibitors were defined. 
ICE cDNA was cloned and expressed, and ICE autoprocessing was analyzed. 
Finally, specific ICE inhibition in human blood plasma by inhibitors was 
investigated . 
ICE could be purified from human monocytes (THP 1 cells) by a three-step 
high performance liquid chromotography procedure. Two subunits of 22 kDa 
(p20) and 10 kDa (plO) were identified that separated in high dilutions of ICE. 
On the N-terminal side of the peptide cleavage site recognized by ICE, three 
amino acids that are followed by an aspartate were required; methylamine was 
sufficient for the C-terminal side (substitutions reduced catalysis by at least 
lOO-fold). 
The best observed peptide substrate was ICE's minimal substrate: Acetyl-Tyr-
Val-Ala-Asp-NH-CH3. Replacing the NH-CH3 with amino-4-methylcoumarin 
yielded a ftuorogenic substrate. Replacement by diazomethylketone, a well-
known cysteine protease inhibitor, led to a potent competitive irreversible 
inhibitor, designated A. Replacement by an aldehyde group led to a transition-
state analog (reversible competitive inhibitor B) . Similarly two other inhibi-
tors (C and D) confirmed together with cystamine and other standard inhibitors 
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that ICE is a cysteine protease. 14C-Iodoacetate labeled the peptide with the 
catalytic cysteine in p20, while inhibitor D enabled the affinity purification of 
active enzyme. 
Degenerate oligonucleotides derived from tryptic peptide sequences led via 
polymerase chain reaction amplification and short cDNAs to full-length 
cDNAs from THP.I cells and human monocytes. Functional expression of ICE 
in COS cells confirmed the cDNA identity. A constitutively expressed tran-
script found in low quantity encodes both subunits of the ICE heterodimer. 
Different 3' untranslated regions could be isolated; the 5' untranslated region 
was extremely short. The resulting ICE amino acid sequence was not found to 
be homologous to any known protein, but the consensus around Ser 289 and 
the catalytic Cys 285 aligned with serine and viral cysteine proteases. 
The primary translation product of the ICE mRNA, the proenzyme (p45), 
could be cleaved by ICE to yield p20 and plO; inhibitor B blocked this process. 
The only other proteins in which the Asp-X bond of the minimal substrate was 
recognized by this high specific protease were human and murine prointerleu-
kin 13. The p45 alone is inactive. Specific inhibition of plasma ICE by inhibitor 
B resulted in a decrease of processed l3-interleukin (mILl-I3) and a corre-
sponding increase in the unprocessed form (pILl-I3) . Controls included the 
weaker effect by the weaker inhibitor C and no effect from other protease in-
hibitors including pepstatin, neutrophil elastase inhibitor. and phosphoramidon. 
COMMENTARY ON THE RESEARCH 
Mature interleukin-113 is a major mediator in inflammation and it has also been 
implicated in septic shock and the healing of wounds. I Attempts to identify 
low-molecular weight antagonists that block the interleukin receptor without 
eliciting an inflammatory response have been so far unsuccessful. Instead, the 
authors concentrated on the interleukin converting enzyme and established it 
to be a cysteine protease of very high specificity. This was not only confirmed 
by molecular cloning of the gene and biochemical analysis but also pharmaco-
logically with a panel of substrates and inhibitors. Inhibition of ICE in blood 
plasma was also demonstrated. 
A prototype of a very highly specific protease has been identified. Further 
studies should elucidate what are the exact cues guiding the enzyme specificity 
and how the three-dimensional structure of the substrate is recognized by the 
enzyme. It will be interesting to determine which other proteases exhibit this 
extremely high specificity. ICE could also have additional functions as it is 
expressed in a wide variety of lymphocytes, as Ceretti et aJ.2 report, who inde-
pendently achieved the cDNA cloning of ICE but did not perform pharmaco-
logical studies. 
On its own p45 is inactive. This implies that there is yet another protease re-
quired for its activation. A whole zymogen cascade, as found in the familiar 
example of blood clotting, can be envisioned. All members of this cascade 
would become potential targets for medical intervention. The findings of 
Thornberry et al. thus open a completely new avenue for immunomodulatory 
drugs. 
As the authors discuss, interleukin-la and tumor necrosis factor can counter-
balance potential effects from modulation of interleukin-ll3. This idea has 
been pursued by Ray et aP who showed that cowpox virus encodes a 38-kDa 
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serine protease inhibitor protein that also acts as an inhibitor of ICE. However, 
the modification of this single cytokine response is not sufficient to inhibit in-
flammatory response and additional cytokine response modifiers seem to be 
secreted by the virus. Similarly other proteases can erase the effect of ICE 
inhibition, particularly if they are only concentrated at sites of inflammation. 4 
Furthermore, clinical tests to assay any therapeutic payoff still need to be per-
formed . Nonetheless, the many possibilities for intervention in this new highly 
specific zymogen pathway should lead to successful new immunomodulatory 
therapies. 
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